Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f98e77d1aba3a9c2fb565cc42cc7c76f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_98036d77295ef99548b053e2cdd21035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60663966e13000e84bef149ef60a69bd |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2008-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a407a915247a985037ad2112cda063f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8778f7cdcfc52f07e0d3cee00056d475 |
publicationDate |
2009-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2009071680-A2 |
titleOfInvention |
Rna antagonist compounds for the modulation of mcl-1 |
abstract |
Oligonucleotides directed against the Mcl-1 gene are developed for modulating the expression of Mcl-1 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Mcl-1. Methods of using these compounds for modulation of Mcl-1 expression and for the treatment of diseases associated with over expression of Mcl-1 are provided. Examples of such diseases include cancer and systemic mastocytosis. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021256297-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018181428-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11065230-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018050801-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021020412-A1 |
priorityDate |
2007-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |